Wealthfront Advisers LLC Acquires New Holdings in DaVita Inc. $DVA

Wealthfront Advisers LLC bought a new stake in DaVita Inc. (NYSE:DVA) in the second quarter, Holdings Channel reports. The fund bought 10,596 shares of the company’s stock, valued at approximately $2,357,000.

Several other large investors have also recently bought and sold shares of the stock. Root Financial Partners LLC raised its position in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares in the last quarter. Caitlin John LLC bought a new position in shares of DaVita in the fourth quarter valued at approximately $34,000. Sankala Group LLC bought a new position in shares of DaVita in the fourth quarter valued at approximately $39,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita during the second quarter valued at approximately $43,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of DaVita during the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.90% of the company’s stock.

DaVita Stock Performance

Shares of NYSE:DVA opened at $175.54 on Friday. The stock has a market capitalization of $11.20 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $247.49. The company has a 50 day moving average price of $215.64 and a 200 day moving average price of $181.58.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts expect that DaVita Inc. will post 14.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Barclays lifted their price target on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. UBS Group raised their target price on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, TD Cowen raised DaVita from a “hold” rating to a “buy” rating and lifted their target price for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $221.75.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.